Abstract 248P
Background
Children receiving palliative care face unique physical and psychosocial needs. Parents may turn to complementary medicines (CM); however, related studies are limited. This study examined the pattern of CM use among pediatric patients with cancer and non-cancer conditions receiving palliative care.
Methods
Between April 2021 and June 2022, parents of patients (<19 years old) receiving palliative care were recruited from 3 hospitals in Hong Kong. They completed a structured survey on sociodemographic data, CM use, and the child’s symptom burden (Rotterdam Symptoms Checklist). Clinical data were collected from health records. Differences in characteristics were compared among CM users (with cancer or non-cancer conditions) and non-users.
Results
We recruited 61 patients (60.7% male; mean age=10.4 years). Overall, 68.9% reported CM use, most commonly Chinese herbal medicine (39.3%) and massage/TuiNa (34.4%). Among the 24 patients with cancer, 62.5% were CM users; they were older at cancer diagnosis than non-users (p<0.001). Non-oral CM approaches, especially acupuncture, were less popular among patients with cancer than non-cancer patients (29.2% vs 64.9%, p=0.01). Among CM users, patients with cancer had higher physical symptom distress than non-cancer users (22.0 vs 17.3, p<0.01). More parents of children with cancer consulted their doctors before using CM than non-cancer users (73.3% vs 33.3% p=0.03), and considered CM to be effective in relieving nausea, vomiting and indigestion symptoms (p<0.05). Most parents (73%) spent ≥USD 130 on CM monthly. Among cancer patients, the most common reason for not using CM was the lack of information (55.6%). Multivariable analyses showed that older parents (aOR=1.15, 95%CI=1.02-1.31) were more likely to use CM, while children who received bone marrow transplant were less likely to use CM (aOR=0.16, 95%CI=0.03-0.73). Most parents (82.5%) supported CM integration, especially Chinese medicine and acupuncture, into palliative care service.
Conclusions
Two-third of surveyed pediatric patients with cancer receiving palliative care used CM regularly. Future work should explore integrating CM approaches into palliative programs for symptom management and psychological support.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
140P - Lenvatinib + everolimus in mRCC that has progressed on immunotherapy: A real-world single center experience
Presenter: CHINNU JOMI
Session: Poster viewing 03
141P - Real-world study of cabozantinib treatment of advanced renal cell carcinoma in Taiwan
Presenter: Yu-Chieh Tsai
Session: Poster viewing 03
143P - Clinical outcomes of systemic therapy for hemodialysis patients with metastatic renal cell carcinoma
Presenter: Shun Iwasa
Session: Poster viewing 03
144P - Association between immune-related adverse events and survival in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab
Presenter: Takanori Hayase
Session: Poster viewing 03
145P - Treatment outcomes and FGFR alterations in unresectable locally advanced or metastatic urothelial cancer in Taiwan
Presenter: Jian-Ri Li
Session: Poster viewing 03
146P - Comparison of the survival outcomes between primary and secondary muscle-invasive bladder cancer: A propensity score-matched Chinese cohort
Presenter: WAICHAN LOK
Session: Poster viewing 03
Resources:
Abstract
147P - Activity of single-agent PD-1/PD-L1 inhibitors in 1st-line (1L) “platinum-ineligible” patients (pts) with metastatic urothelial cancer (mUC) in real-life clinical practice
Presenter: Javier Molina Cerrillo
Session: Poster viewing 03
149P - A need for clear definitions and improved management for BCG-unresponsive tumors in Asia-Pacific
Presenter: Lui Shiong Lee
Session: Poster viewing 03
Resources:
Abstract